Fast Five Quiz: Can You Diagnose Waldenström Macroglobulinemia?

Emmanuel C. Besa, MD

Disclosures

March 13, 2019

The monoclonal antibody rituximab, given in combination with the alkylating agent bendamustine or a proteasome inhibitor (eg, bortezomib, carfilzomib [off-label use]; ixazomib [for patients with WM cells resistant to ibrutinib]), is the typical treatment for WM.

Other therapies for WM include alkylating agents, purine nucleoside analogues, immunomodulatory medications, mammalian target of rapamycin inhibitors, and monoclonal antibodies.

Corticosteroids and various antineoplastic medications (tyrosine kinase inhibitor, alkylating, antimetabolite, anthracycline, proteasome inhibitors, and monoclonal antibody) are also treatment options for WM.

Antibiotic agents of any class, methylprednisolone, and combination beta-blocker and corticosteroid therapy are not appropriate or effective in treating WM.

For more on treatment and management options for WM, read here.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....